Cargando…
Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab
INTRODUCTION: Approximately 3%–10% of asthma patients will remain uncontrolled despite maximum, optimal conventional therapy. Treatment of severe refractory asthma often involves the use of targeted biological therapy. Randomised controlled trials have shown improvements in clinical parameters with...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845591/ https://www.ncbi.nlm.nih.gov/pubmed/36686966 http://dx.doi.org/10.3389/falgy.2022.1052339 |